Datamonitor launches
Licensing Review
The Licensing Review
contains news, analysis and opinion on the healthcare licensing industry.
It covers all the month's major issues and events in drug licensing and
pharma alliances/joint ventures.
Scope
-
Strategic insight
into the future shape of healthcare companies and markets
-
The most significant
healthcare licensing news compiled into one monthly update
-
Expert analysis into
the implications of the month's important healthcare licensing events
-
Insight into the
future shape of the market for players at all levels
-
All the month's
healthcare licensing stories in headline and summary form
Report Highlights
Out of the dozens of
topics covered in this month's review, the most important include:
* Pharmaceutical giant
Pfizer will co-promote Swiss biotech Serono's multiple sclerosis drug
Rebif in the US. With strong clinical evidence in its favor, an
established position elsewhere in the world, and marketing support from
the US' leading neurology player, Rebif now looks set to dominate the US
MS market.
* The International AIDS
Vaccine Initiative launched a consortium seeking to develop a vaccine for
the virus. The new consortium will involve leading AIDS laboratories
working with the US government's Vaccine Research Center.
Reasons to Purchase
Not only keeps you
updated about industry events - it also gives you opinion and insight
Draws upon Datamonitor
analysts' extensive experience to bring you our perspective on the impact
of the latest events
Provides you with your
own news archive to track company and industry progress, giving you an
extensive reference to relevant events and issues
View
pdf brochure
Click
here to purchase online
